Advent France Biotechnology launches second fund with a first close at EUR86m
Advent France Biotechnology (AFB), an AMF-regulated investment company dedicated to life sciences, has held the first closing of its second fund at EUR86 million (USD102 million). The European Investment Fund (EIF) and the Fonds national d’amorçage 2 (the French Seed Fund 2) managed on behalf of the French State by